Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial Score (Unknown)
- New search for: Harton, Joanna
- New search for: Segal, Brian
- New search for: Mamtani, Ronac
- New search for: Mitra, Nandita
- New search for: Hubbard, Rebecca A.
- New search for: Harton, Joanna
- New search for: Segal, Brian
- New search for: Mamtani, Ronac
- New search for: Mitra, Nandita
- New search for: Hubbard, Rebecca A.
In:
Statistics in Biopharmaceutical Research
;
15
, 2
;
408-420
;
2023
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial Score
-
Contributors:Harton, Joanna ( author ) / Segal, Brian ( author ) / Mamtani, Ronac ( author ) / Mitra, Nandita ( author ) / Hubbard, Rebecca A. ( author )
-
Published in:Statistics in Biopharmaceutical Research ; 15, 2 ; 408-420
-
Publisher:
- New search for: Taylor & Francis
-
Publication date:2023-04-03
-
Size:13 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:Unknown
-
Keywords:
-
Source:
Table of contents – Volume 15, Issue 2
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 235
-
Statistics in Biopharmaceutical Research Best Papers Award 2023Hamasaki, Toshimitsu / Cooner, Freda et al. | 2023
- 237
-
Editor’s Note: Special Section on Estimands, Design and Analysis of Clinical Trials with Time-to-Event OutcomesHamasaki, Toshimitsu et al. | 2023
- 238
-
Estimands for Recurrent Event Endpoints in the Presence of a Terminal EventSchmidli, Heinz / Roger, James H. / Akacha, Mouna et al. | 2023
- 249
-
Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”James Hung, H. M. / Wang, Sue-Jane et al. | 2023
- 251
-
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”Janvin, Matias / Young, Jessica G. / Stensrud, Mats J. et al. | 2023
- 255
-
Rejoinder to Commentaries on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”Schmidli, Heinz / Roger, James H. / Akacha, Mouna / on behalf of the Recurrent Event Qualification Opinion Consortium et al. | 2023
- 257
-
Properties of Two While-Alive Estimands for Recurrent Events and Their Potential EstimatorsWei, Jiawei / Mütze, Tobias / Jahn-Eimermacher, Antje / Roger, James et al. | 2023
- 268
-
Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First Event Endpoints in the Presence of Terminal Events—Application to Clinical Trials in Chronic Heart FailureFritsch, Arno / Schlömer, Patrick / Mendolia, Franco / Mütze, Tobias / Jahn-Eimermacher, Antje / on behalf of the Recurrent Event Qualification Opinion Consortium et al. | 2023
- 280
-
Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working GroupRoychoudhury, Satrajit / Anderson, Keaven M / Ye, Jiabu / Mukhopadhyay, Pralay et al. | 2023
- 295
-
The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance form a Cross-Pharma Working Group.”Magirr, Dominic / Burman, Carl-Fredrik et al. | 2023
- 297
-
Comment on “Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group”: The Test Statistic Should Estimate Some Reasonable Measure of Treatment BenefitSnapinn, Steven / Jiang, Qi / Ke, Chunlei et al. | 2023
- 300
-
Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical TrialsShen, Yuan-Li / Wang, Xin / Sirisha, Mushti / Mulkey, Flora / Zhou, Jiaxi / Gao, Xin / Zhang, Lijun / Gwise, Thomas / Tang, Shenghui / Theoret, Marc et al. | 2023
- 310
-
Testing and Interpreting the “Right” Hypothesis—Comment on “Non-proportional Hazards — An Evaluation of the MaxCombo Test in Cancer Clinical Trials”Posch, Martin / Ristl, Robin / König, Franz et al. | 2023
- 312
-
Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working GroupLin, Ray S. / Mukhopadhyay, Pralay / Roychoudhury, Satrajit / Anderson, Keaven M. / Hu, Tianle / Huang, Bo / Leon, Larry F. / Liao, Jason J. Z. / Lin, Ji / Liu, Rong et al. | 2023
- 315
-
Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”Shen, Yuan-Li / Mushti, Sirisha / Mulkey, Flora / Gwise, Thomas / Wang, Xin / Zhou, Jiaxi / Gao, Xin / Tang, Shenghui / Theoret, Marc R. / Pazdur, Richard et al. | 2023
- 318
-
Composite Endpoints in Cardio-Renal Clinical Outcome TrialsHung, H. M. James / Lawrence, John et al. | 2023
- 323
-
The Choice of a Randomization Procedure in Survival Studies with Nonproportional HazardsRückbeil, Marcia Viviane / Manolov, Martin / Hilgers, Ralf-Dieter et al. | 2023
- 332
-
Combined Tests Based on Restricted Mean Time Lost for Competing Risks DataLyu, Jingjing / Hou, Yawen / Chen, Zheng et al. | 2023
- 340
-
Closed-Form Approximation of Correlation Matrix Among Fleming Harrington Test Statistics in MaxCombo Test: Comments on “Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group”Kundu, Madan G. et al. | 2023
- 343
-
Survey and Recommendations on the Use of P-Values Driving Decisions in Nonclinical Pharmaceutical ApplicationsAltan, Stan / Amaratunga, Dhammika / Cabrera, Javier / Garren, Jeonifer / Geys, Helena / Kolassa, John / LeBlond, David / Li, Dingzhou / Liao, Jason / Liu, Jia et al. | 2023
- 359
-
Estimands for Continuous Longitudinal Outcomes in the Presence of Treatment Discontinuation—A Simulation Study in Hyperkalemia TreatmentsTsuchikawa, Masaru / Sakamaki, Kentaro et al. | 2023
- 372
-
Quantifying Replicability and Consistency in Systematic ReviewsJaljuli, Iman / Benjamini, Yoav / Shenhav, Liat / Panagiotou, Orestis A. / Heller, Ruth et al. | 2023
- 386
-
A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s DiseaseLasch, Florian / Guizzaro, Lorenzo / Pétavy, Frank / Gallo, Ciro et al. | 2023
- 400
-
Assessing the Impacts of Cluster Effects and Covariate Imbalance in Cluster Randomized Equivalence TrialsFicek, Joseph / Chen, Henian / Lu, Yuanyuan / Huang, Yangxin / Mayer, John M. et al. | 2023
- 408
-
Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial ScoreHarton, Joanna / Segal, Brian / Mamtani, Ronac / Mitra, Nandita / Hubbard, Rebecca A. et al. | 2023
- 421
-
Hypothetical Estimands in Clinical Trials: A Unification of Causal Inference and Missing Data MethodsOlarte Parra, Camila / Daniel, Rhian M. / Bartlett, Jonathan W. et al. | 2023
- 433
-
On Variance Estimation for the One-Sample Log-Rank TestDanzer, Moritz Fabian / Faldum, Andreas / Schmidt, Rene et al. | 2023
- 444
-
Cancer Clinical Trials beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum DiscussionSridhara, Rajeshwari / Barksdale, Elizabeth / Marchenko, Olga / Jiang, Qi / Ando, Yuki / Bloomquist, Erick / Coory, Michael / Crouse, Melissa / Degtyarev, Evgeny / Framke, Theodor et al. | 2023
- 450
-
Evaluation of Treatment Effect in Underrepresented Population in Cancer Trials: Discussion with International RegulatorsSridhara, Rajeshwari / Marchenko, Olga / Jiang, Qi / Barksdale, Elizabeth / Chen, Jie / Dreyer, Nancy / Fashoyin-Aje, Lola / Garrett-Mayer, Elizabeth / Gormley, Nicole / Dr.Gwise, Thomas et al. | 2023